Phathom Pharmaceuticals (PHAT) Current Leases (2019 - 2026)
Phathom Pharmaceuticals (PHAT) reported Current Leases of $667000.0 for Q1 2026, up 111.08% year-over-year from $316000.0 in Q1 2025, and up 2.93% quarter-over-quarter from $648000.0 in Q4 2025.
Phathom Pharmaceuticals (PHAT) Current Leases (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 8 years of Current Leases data on file, last reported at $667000.0 in Q1 2026.
- Current Leases for Q1 2026 came in at $667000.0, up 111.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $667000.0 (up 111.08% YoY), and the FY2025 annual result was $648000.0, up 29.34% from the prior year.
- Current Leases climbed to $667000.0 in Q1 2026 per PHAT's latest filing, from $648000.0 in the prior quarter.
- Over five years, Current Leases peaked at $730000.0 in Q1 2024 and troughed at $238000.0 in Q2 2025.
- A 5-year average of $616352.9 and a median of $680000.0 in 2024 frame the typical range for Current Leases.
- The sharpest annual moves came in 2025 and 2026: Current Leases slumped 66.94% in 2025, then surged 111.08% in 2026.
- A 5-year view of Current Leases shows it stood at $708000.0 in 2022, then advanced by 2.54% to $726000.0 in 2023, then slumped by 30.99% to $501000.0 in 2024, then gained by 29.34% to $648000.0 in 2025, then gained by 2.93% to $667000.0 in 2026.
- Business Quant data shows PHAT's Current Leases at $667000.0 in Q1 2026, $648000.0 in Q4 2025, and $591000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | 667,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 667,000.00 |
| Dec 31, 2025 | 648,000.00 |
| Sep 30, 2025 | 591,000.00 |
| Jun 30, 2025 | 238,000.00 |
| Mar 31, 2025 | 316,000.00 |
| Dec 31, 2024 | 501,000.00 |
| Sep 30, 2024 | 680,000.00 |
| Jun 30, 2024 | 720,000.00 |
| Mar 31, 2024 | 730,000.00 |
| Dec 31, 2023 | 726,000.00 |
| Sep 30, 2023 | 721,000.00 |
| Jun 30, 2023 | 717,000.00 |
| Mar 31, 2023 | 712,000.00 |
| Dec 31, 2022 | 708,000.00 |
| Sep 30, 2022 | 685,000.00 |
| Jun 30, 2022 | 628,000.00 |
| Mar 31, 2022 | 490,000.00 |
| Dec 31, 2021 | 487,000.00 |
| Sep 30, 2021 | 484,000.00 |
| Jun 30, 2021 | 480,000.00 |